Results 201 to 210 of about 62,685 (235)
Some of the next articles are maybe not open access.
Emerging drugs for urothelial carcinoma
Expert Opinion on Emerging Drugs, 2013Advanced urothelial carcinoma is associated with a poor prognosis. In the metastatic setting, the response rate to first-line, cisplatin-containing chemotherapy is high, but survival is poor. Second-line treatment options are limited. Advanced age at diagnosis and the presence of comorbidities often preclude treatment with cisplatin-containing regimens.
Benjamin A, Gartrell, Guru, Sonpavde
openaire +2 more sources
Urothelial Carcinoma of the Kidney and Ureter
British Journal of Urology, 1980Summary— Two hundred and three patients with upper tract urothelial tumours were reviewed. Eighty had pelvicaliceal tumours, 90 ureteric tumours, and 33 multifocal tumours of both pelvis and ureter. Two hundred patients had transitional cell carcinomas and 3 had squamous cell carcinomas.
C M, Booth, K M, Cameron, R C, Pugh
openaire +2 more sources
Erdafitinib to treat urothelial carcinoma
Drugs of Today, 2019Erdafitinib is the first Food and Drug Administration (FDA)-approved oral pan-fibroblast growth factor receptor (FGFR) kinase inhibitor that binds to four FGFRs (FGFR-1 to -4), leading to decreased cell signaling and cellular apoptosis. Erdafitinib also binds to RET, colony-stimulating factor 1 receptor (CSF-1R), platelet-derived growth factor receptor
openaire +2 more sources
Erdafitinib in Urothelial Carcinoma
New England Journal of Medicine, 2019Guru, Sonpavde, Gottfrid, Sjödahl
openaire +3 more sources
Molecular classification and diagnostics of upper urinary tract urothelial carcinoma
Cancer Cell, 2021Kenichi Yoshida +2 more
exaly
Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma
European Urology Focus, 2021Sumanta K. Pal, Andrea Necchi
exaly
What Is the Significance of Variant Histology in Urothelial Carcinoma?
European Urology Focus, 2020Jianjun Gao +2 more
exaly